Clinical trials: Lipodystrophy
Facial Lipoatrophy
Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)
5 year, open-label study to evaluate safety of SCULPTRA on the signs of lipoatrophy of the face in at least 100 evaluable subjects with human immunodeficiency virus.
- Trial name
- FACES (NCT00360932)
- Testing
- SCULPTRA (poly-L-lactic acid injection)
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Bausch Health Americas, Inc.
Generalized Lipodystrophy
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or…
- Trial name
- NCT06502990
- Testing
- Metreleptin
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 1 people
- Sponsor
- Amryt Pharma
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
- Trial name
- NCT00005106
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaxo Wellcome
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
HIV-associated Lipodystrophy Syndrome
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
This will be a two-part study in healthy adults. Part A is a phase 1, non-randomized, open label, single-dose, single-centre mass balance study utilizing a radiolabeled dose to investigate the recovery, excretion, and…
- Trial name
- NCT01848340
- Testing
- GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Familial Partial Lipodystrophy
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
- Trial name
- NCT03514420
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Akcea Therapeutics
Generalized Lipodystrophy
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD).
- Trial name
- LAGO (NCT07220785)
- Testing
- Mibavademab
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Laxity, Lipodystrophy
The PREFORM Study: Rotational Fractional Resection for Submental Contouring
This study will evaluate the safety and efficacy of rotational fractional resection (RFR) to improve neck contouring. Rotational fractional resection is used to remove loose skin and fat.
- Trial name
- NCT03966924
- Testing
- Rotational fractional resection (1.5mm Diameter Device)
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Recros Medica, Inc.
Volume Deficit in the Mid-face
A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment
To compare the safety and efficacy profiles of Revanesse Shape + with Lidocaine versus Juvederm Voluma with Lidocaine for subcutaneous and/or supraperiosteal injection to improve appearance through the correction of age-related…
- Trial name
- NCT04927052
- Testing
- Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine.
- Where
- 7 sites in Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Prollenium Medical Technologies Inc.
Familial Partial Lipodystrophy
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in a randomized treatment (RT) period in participants with familial partial lipodystrophy (FPL).
- Trial name
- NCT02527343
- Testing
- volanesorsen
- Where
- 12 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Akcea Therapeutics
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
This is an expanded access designed to provide metreleptin for the treatment of diabetes mellitus and/or hypertriglyceridemia associated with lipodystrophy.
- Trial name
- NCT00677313
- Testing
- metreleptin
- Sponsor
- Bristol-Myers Squibb
Familial Partial Lipodystrophy
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
- Trial name
- NCT06679270
- Testing
- Metreleptin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
HIV Infections
A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
The purpose of this study is to see if it is safe and effective to give the protease inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems associated with other PIs.
- Trial name
- NCT00002417
- Testing
- Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Facial Lipoatrophy, Morphological Asymmetry of the Face
Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars
In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® VOLUME, and then will return for follow-up assessments…
- Conditions
- Facial Lipoatrophy, Morphological Asymmetry of the Face, Debilitating Scars
- Trial name
- FLASH2 (NCT03050749)
- Testing
- Princess® VOLUME
- Where
- 3 sites in Austria
- Volunteers
- 56 people
- Sponsor
- Croma-Pharma GmbH
Facial Lipoatrophy (FLA)
Evaluation of HA Dermal Fillers in the Treatment of Pathological Facial Lipoatrophy
Facial lipoatrophy (FLA) refers to the loss of adipose tissue and is manifested by flattening or indentation of convex contours of the face.
- Trial name
- HAtrophy (NCT05776836)
- Testing
- Dermal filler
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Symatese
Facial Lipoatrophy, Morphological Asymmetry of the Face
Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars
In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® FILLER, and then will return for follow-up assessments…
- Conditions
- Facial Lipoatrophy, Morphological Asymmetry of the Face, Debilitating Scars
- Trial name
- FLASH 1 (NCT03050723)
- Testing
- Princess® FILLER
- Where
- 3 sites in Austria
- Volunteers
- 53 people
- Sponsor
- Croma-Pharma GmbH
Lipodystrophy, Cellulitis
Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat
PURPOSE: To evaluate the efficacy of shock waves extracorporea in improving body contour,decrease fat localized and appearance of gynoid lipodystrophy.
- Conditions
- Lipodystrophy, Cellulitis, Adiposity
- Trial name
- ESWT (NCT03275259)
- Testing
- THORK Shock Wave® (Extracorporeal shock waves)
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Nasolabial Folds, Lipoatrophy
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of…
- Conditions
- Nasolabial Folds, Lipoatrophy, Lipodystrophy
- Trial name
- NCT02647853
- Testing
- TAT4 Gel concentration A, TAT4 Gel concentration B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Topokine Therapeutics, Inc.